Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443300 · ClinicalTrials.gov registry record
Effectiveness of Protected Environment Rooms for AML and MDS
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 3
- Enrollment target
NCT00443300: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT00443300 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443300 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the "protected environment" (PE) can help to prevent infections in patients aged 60 and above who are receiving what is considered low-intensity treatment for newly-diagnosed AML or high-risk MDS.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00443300
The ClinicalTrials.gov registry entry for NCT00443300 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00443300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00443300 about?
NCT00443300 is a clinical study titled "Effectiveness of Protected Environment Rooms for AML and MDS". The goal of this clinical research study is to learn if the "protected environment" (PE) can help to prevent infections in patients aged 60 and above who are receiving what is considered low-intensity treatment for newly-diagnosed AML or high-risk MDS.
What is the current status of trial NCT00443300?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2007-01. Estimated completion is 2008-01.
Who is sponsoring clinical trial NCT00443300?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.